Open AccessPodoplanin: An emerging cancer biomarker and therapeutic target
Author(s) -
Krishnan Harini,
Rayes Julie,
Miyashita Tomoyuki,
Ishii Genichiro,
Retzbach Edward P.,
Sheehan Stephanie A.,
Takemoto Ai,
Chang YaoWen,
Yoneda Kazue,
Asai Jun,
Jensen Lasse,
Chalise Lushun,
Natsume Atsushi,
Goldberg Gary S.
Publication year - 2018
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13580
Subject(s) - podoplanin , cancer research , medicine , cancer , biomarker , cancer cell , inflammation , cancer associated fibroblasts , metastasis , tumor progression , melanoma , immunology , biology , immunohistochemistry , biochemistry
Podoplanin ( PDPN ) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR ‐T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.